Yishai Ofran

Shaare Zedek Medical Center — Israel

Medicine · Health Sciences

31h-index3.8kcitations194works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(111), Acute Lymphoblastic Leukemia research(38), Chronic Myeloid Leukemia Treatments(29), Hematopoietic Stem Cell Transplantation(27), Histone Deacetylase Inhibitors Research(21)

Publications193 total

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party
Blood·2025· 1 citedOpen Access
Subclinical cardiac changes following CPX-351 induction in adults with favorable/intermediate-risk AML
Blood·2025Open Access
Prospective study of patient-reported depression, and cognitive and functional impairment, and impact on survival and induction mortality in fit adults age ≥60 years receiving intensive chemotherapy (IC) for Acute Myeloid Leukemia (AML): Prospective geriatric assessment (GA) report from ECOG-ACRIN (EA) E2906 randomized study
Blood·2025
Therapeutic potential of mitochondrial transplantation in the treatment of MDS
Blood·2025Open Access
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS
Blood Advances·2025· 4 citedOpen Access
<scp>HiDAC</scp> Consolidation in <scp>AML</scp> : Comparable Outcomes With Reduced Toxicity Using a Three‐Day Schedule ( <scp>HiDAC</scp> ‐123)
European Journal Of Haematology·2025Open Access
Epiglottitis in Patients Treated for Acute Leukemia – Case Series and Systematic Review of the Literature
Acta Haematologica·2025Open Access
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia – the CONS
Haematologica·2025Open Access
Post‐Relapse Outcomes of Older Patients With <i>NPM1</i>‐Mutated <scp>AML</scp> Are Favorable With Allo Transplant in Second Remission
European Journal Of Haematology·2024· 4 citedOpen Access
CPX‐351 +/− gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable‐intermediate risk, FLT3‐ITD negative, AML: A pilot study
British Journal of Haematology·2024· 1 citedOpen Access
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study
Blood Advances·2024· 5 citedOpen Access
Acute myeloid leukemia drug-tolerant persister cells survive chemotherapy by transiently increasing plasma membrane rigidity, that also increases their sensitivity to immune cell killing
Haematologica·2024· 3 citedOpen Access
Mitochondrial Augmentation of Hematopoietic Stem and Progenitor Cells As a New Therapeutic Approach for Myelodysplasia
Blood·2024
Templated Insertion Mediates Generation of p190 BCR/ABL Facilitating CML Heterogeneity Uniquely Detected By Optical Genome Mapping
Blood·2024Open Access
464 (PB452): Determination of the phase 2 dose of AU-007, an AI-designed human monoclonal antibody that redirects IL-2 to T-effector cells
European Journal of Cancer·2024
Interactions between immune cell types facilitate the evolution of immune traits
Nature·2024· 14 citedOpen Access
POS0465 A NOVEL THERAPEUTICALLY ACTIVE ANTI-TNFR2 AGONISTIC ANTIBODY PROMOTES TREG PROLIFERATION AND INDUCTION OF TREG FUNCTIONAL MARKERS
Annals of the Rheumatic Diseases·2024
Gilteritinib with or without venetoclax for relapsed/refractory <i>FLT3</i>‐mutated acute myeloid leukaemia
British Journal of Haematology·2024· 5 cited
The Effect of Mind-Body Intervention on Lymphocyte Doubling Time and Treatment-Free Survival in Treatment-Naïve Chronic Lymphocytic Leukemia Patients
Acta Haematologica·2024
Intensive induction in older patients with acute myeloid leukemia: an initial struggle with later rewards?
Haematologica·2024Open Access
page 1 of 10Next →

Frequent Co-authors

Jacob M. Rowe(14), Avraham Frisch(8), Tsila Zuckerman(7), Ofir Wolach(7), Martin S. Tallman(6), Ron Ram(6), Yakir Moshe(6), Gert J. Ossenkoppele(5), Gail J. Roboz(5), Israel Henig(5), Chezi Ganzel(5), Arie Apel(5), Maya Koren‐Michowitz(5), Farhad Ravandi(4), Agnieszka Wierzbowska(4), Andrew H. Wei(4), Pau Montesinos(4), Jessica K. Altman(4), Ilana Hellmann(4), Arnon Nagler(4)